A. Tybjærg-Hansen

Surgery · 2010–2017

A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Surgery — 77 citations into it; #736 of 1,106 by trust here, #159 by citations
• Endocrinology, Diabetes and Metabolism — 68 citations into it; #249 of 623 by trust here, #146 by citations
• Epidemiology — 19 citations into it

Whom A. Tybjærg-Hansen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Børge G. Nordestgaard
2. Deborah Lawlor

Who trusts A. Tybjærg-Hansen overall

1. Børge G. Nordestgaard

Papers from A. Tybjærg-Hansen's perspective

Ordered by how strongly the researchers A. Tybjærg-Hansen trusts endorse each paper. Same corpus, a different order for every researcher.

1. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. (Journal of the American Medical Association (JAMA))
2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (Journal of the American College of Cardiology)
3. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology (Statistics in Medicine)
4. Mendelian randomization: prospects, potentials, and limitations. (International Journal of Epidemiology)
5. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans (Nature Genetics)
6. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
7. Inflammation, Atherosclerosis and Coronary Artery Disease (Clinical Medicine Insights: Cardiology)
8. Safety of anacetrapib in patients with or at high risk for coronary heart disease. (New England Journal of Medicine)
9. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
10. A global reference for human genetic variation

Their papers

• Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease (2017) — 750 citations
• Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes (2017) — 401 citations
• Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) — 768 citations
• Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease (2014) — 1,133 citations
• Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. (2014) — 886 citations
• Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) — 765 citations
• Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) — 2,141 citations
• Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation (2013) — 604 citations
• Remnant cholesterol as a causal risk factor for ischemic heart disease. (2013) — 1,030 citations
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011) — 1,241 citations
• Lipoprotein(a) as a cardiovascular risk factor: current status (2010) — 1,754 citations